Table 2.
Infection and treatment details§
| ID | Time (days) from LVAD implantation to infection onset | Type of LVAD-related infection |
Primary pathogen | Infection type | Concomitant infection during the index hospitalization | Number of hospitalizations due to infection before index stay | Duration of oral outpatient abx before t he index hospitalization |
Duration of the index hospital stay | Targeted abx for primary pathogen | Surgical debridement | Number of oritavancin doses | Time of consequtive doses; (DX-numember of dose Xd -number of days from the first dose) |
Maintainance oral abx after first oritavancine dose | OHT | Time (days) from the first oritavancine dose to OHT | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 714 | SSI (minitoracothomy) | E. faecalis | relapse | E. faecalis: urinary and BSI S. hominis: BSI K. pneumoniae ESBL: LVAD-related infection | 3 | 0 | 48 (43) days | vancomycin, meropenem | in previous and index hospital stay | 3 | D1-0d; D2-21d; D3-44d | no | yes | 142 days | cure |
| II | 506 | deep DLI | Corynebacterium spp. | primary | no | 0 | NA | 42 (41) days | vancomycin | in the index hospital stay | 1 | D1-0d, D2-21d | NA | no | NA | cure |
| III | 639 | deep DLI | S. aureus (MSSA) | primary | no | 0 | NA | 36 (27) days | cloxacillin, rifampicin, gentamycin | in the index hospital stay | 2 | D1-0d, D2-21 | 2 weeks prophylaxis with TMP-SMX | yes | 30 days | cure |
| IV | 199 | deep DLI | S. aureus (MSSA) | primary | no | 0 | NA | 33 (33) days | cloxacillin, rifampicin | no | 1 | D1-0d | 3 -week treatment: cloxacililin and rifampicin | no | NA | cure |
| V | 392 | deep DLI | S. aureus (MSSA) | relapse | no | 0 (only ambulatory treatment) | 26 | 35 (35) days | cloxacillin, rifampicin, gentamycin | in the index hospital stay | 2 | D1-0d, D2-14d | 4-week treatment: cloxacililin and rifampicin | yes | 69 days | cure |
| VI | 2088 | deep DLI | St. Capitis (MRCNS) Achromobacter xylosixidnas, Corynebacterium amycolatum. | primary | S. epidermids: BSI | 0 | NA | 56 (54) days | Piperacillin-tazobactam vancomycin | in the index hospital stay | 1 | D1-0 | NA | yes | 130 days | failure |
| VIIa | 149 | deep DLI | S. aureus (MSSA) | relapse and failure of index standard treatment based on PET | no | 1 | 14 | 5 (5) days | cloxacillin | no | 2 | D1-0d, D2-20d | no | no | NA | cure |
| VIIIa | 323 | deep DLI | S.aureus (MSSA) | primary | no | 0 | NA | 24 (24) days | cloxacillin, rifampicin | no | 2 | D1-0, D2-28d | 6-week treatment: cloxacililin and rifampicin | no | NA | cure |
| IX | 1162 | deep DLI | S. aureus (MSSA) | relapse | 1 | 1 | 14 | 31 (31) days | cloxacillin, rifampicin | no | 2 | D1-0d, D2-14d | no | no | NA | cure |
| X | 94 | SSI (sternotomy) | E. faecium (VRE); S. epidermidis (MRCNS) | relapse and failure of index standard treatment based on PET | no | 1 | 30 | 22 (19) days | vancomycin | no | 2 | D1-0d, D2-24d | no | no | NA | cure |
Abx Antibiotics, OHT Orthotopic heart transplantation, D -day, NA Not applicable, TMP-SMX Trimethoprim- sulfamethoxazole
aThe episodes belong to the same patient